CeriBell (NASDAQ:CBLL - Get Free Report)'s share price shot up 4.9% during trading on Monday . The company traded as high as $24.38 and last traded at $24.38. 81,872 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 189,637 shares. The stock had previously closed at $23.24.
Wall Street Analyst Weigh In
Several research firms have commented on CBLL. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. TD Cowen increased their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $32.60.
Check Out Our Latest Stock Analysis on CBLL
CeriBell Stock Performance
The firm's fifty day moving average price is $23.00.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. As a group, research analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.
Institutional Trading of CeriBell
Several large investors have recently added to or reduced their stakes in CBLL. FMR LLC acquired a new stake in shares of CeriBell during the fourth quarter worth about $128,120,000. TPG GP A LLC purchased a new position in CeriBell during the 4th quarter worth approximately $102,677,000. Red Tree Management LLC purchased a new stake in shares of CeriBell in the 4th quarter valued at $57,083,000. Yu Fan acquired a new position in CeriBell during the fourth quarter valued at $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new position in shares of CeriBell in the 4th quarter valued at about $28,160,000.
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Recommended Stories
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
